Abstract
Currently, from 15 to 50% of the population in the developed countries has obesity. Overall, patients with obesity have a higher risk of infection; they are more likely to develop infectious complications after surgical interventions and have a higher mortality rate. Administration of antimicrobial therapy to obese patients is difficult due to changes in pharmacokinetics of antibiotics in such patients. Despite the importance of antibiotic dosing in patients with overweight and obesity, there is a lack of research in this area of clinical pharmacology. This review summarizes the currently available studies and literature data on approaches to antibiotic dosing in obese patients.
Institute of Antimicrobial Chemotherapy, Smolensk, Russia
Institute of Antimicrobial Chemotherapy, Smolensk, Russia
Institute of Antimicrobial Chemotherapy, Smolensk, Russia
-
1.
Ng M., Fleming T., Robinson M., et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 19802013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384(9945):766-781.
-
2.
Go A.S., Mozaffarian D., Roger V.L., et al; on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics – 2013 update: a report from the American Heart Association. Circulation. 2013;127:e6-e245.
-
3.
Sturm R., Hattori A. Morbid obesity rates continue to rise rapidly in the United States. Int J Obes (Lond). 2013;37(6):889-891.
-
4.
Sturm R. Increases in morbid obesity in the USA: 2000-200
-
5.
Public Health. 2007;121:492-495.
-
6.
Finkelstein E.A., Khavjou O.A., Thompson H., et al. Obesity and severe obesity forecasts through 2030. Am J Prev Med. 2012;42(6):563-570. 6. Falagas M.E., Athanasoulia A.P., Peppas G., et al. Effect of body mass index on the outcome of infections: a systematic review. Obes Rev. 2009;10:280289.
-
7.
Liu Y., Dong Y., Wu X., et al. Influence of high body mass index on mortality and infectious outcomes in patients who underwent open gastrointestinal surgery: A meta-analysis. Am J Infect Control. 2016;44(5):572-578.
-
8.
Hanley M.J., Abernethy D.R., Greenblat D.J. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010;49:7187.
-
9.
Tucker C.E., Lockwood A.M., Nguyen N.H. Antibiotic dosing in obesity: the search for optimum dosing strategies. Clin Obes. 2014;4(6):287-295.
-
10.
Arabi Y.M., Dara S.I., Tamim H.M., et al. Clinical characteristics, sepsis interventions and outcomes in the obese patients with septic shock: an international multicenter cohort study. Crit Care. 2013;17:R72.
-
11.
Roe J.L., Fuentes J.M., Mullins M.E. Underdosing of common antibiotics for obese patients in the ED. Am J Emerg Med. 2012;30:1212-1214.
-
12.
Longo C., Bartlett G., Macgibbon B., et al. The effect of obesity on antibiotic treatment failure: a historical cohort study. Pharmacoepidemiol Drug Saf. 2013;22:970-976.
-
13.
WHO. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. WHO Technical Report Series 854. Geneva: World Health Organization, 1995.
-
14.
WHO. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation. WHO Technical Report Series 894. Geneva: World Health Organization, 2000.
-
15.
Al-Dorzi H.M., Al Harbi S.A., Arabi Y.M. Antibiotic therapy of pneumonia in the obese patient: dosing and delivery. Curr Opin Infect Dis. 2014;27(2):165-173.
-
16.
Pai M.P., Bearden D.T. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy. 2007;27(8):1081-1091.
-
17.
Janson B., Thursky K. Dosing of antibiotics in obesity. Curr Opin Infect Dis. 2012;25(6):634-649.
-
18.
Udy A.A., Roberts J.A., Lipman J. Clinical implications of antibiotic pharmacokinetic principles in the critically ill. Intensive Care Med. 2013;39:2070-2082.
-
19.
Brill M.J., Diepstraten J., van Rongen A., et al. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet. 2012;51(5):277-304.
-
20.
West G.B., Brown J.H., Enquist B.J. A general model for the origin of allometric scaling laws in biology. Science. 1997;276(5309):122-126.
-
21.
Claus B.O., Hoste E.A., Colpaert K., et al. Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy. J Crit Care. 2013;28:695-700.
-
22.
Payne K.D., Hall R.G. 2nd. Dosing of antibacterial agents in obese adults: does one size fit all? Expert Rev Anti Infect Ther. 2014;12(7):829-854.
-
23.
Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
-
24.
Winter M.A., Guhr K.N., Berg G.M. Impact of various body weights and serum creatinine concentrations on the bias and accuracy of the CockcroftGault equation. Pharmacotherapy. 2012;32(7):604-612.
-
25.
Anderson A.H., Yang W., Hsu C.Y., et al. Estimating GFR among participants in the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2012;60:250-261.
-
26.
Aggarwal N., Porter A.C., Tang I.Y., et al. Creatinine-based estimations of kidney function are unreliable in obese kidney donors. J Transplant. 2012;2012:872-894.
-
27.
Wurtz R., Itokazu G., Rodvold K. Antimicrobial dosing in obese patients. Clin Infect Dis. 1997;25:112-118.
-
28.
Yuk J., Nightingale C.H., Sweeney K., et al. Pharmacokinetics of nafcillin in obesity. J Infect Dis. 1988;157(5):1088-1089.
-
29.
Cheadle W.G. Risk factors for surgical site infection. Surg Infect (Larchmt). 2006;7(Suppl 1):S7-11.
-
30.
Forse R.A., Karam B., MacLean L.D., Christou N.V. Antibiotic prophylaxis for surgery in morbidly obese patients. Surgery. 1989;106:750-756.
-
31.
Ho V.P., Nicolau D.P., Dakin G.F., et al. Cefazolin dosing for surgical prophylaxis in morbidly obese patients. Surg Infect (Larchmt). 2012;13(1):33-37.
-
32.
van Kralingen S., Taks M., Diepstraten J., et al. Pharmacokinetics and protein binding of cefazolin in morbidly obese patients. Eur J Clin Pharmacol. 2011;67:985-992.
-
33.
Swank M.L., Wing D.A., Nicolau D.P., et al. Increased 3-gram cefazolin dosing for cesarean delivery prophylaxis in obese women. Am J Obstet Gynecol. 2015;213(3):415.e1-8.
-
34.
Barbour A., Schmidt S., Rout W.R., et al. Soft tissue penetration of cefuroxime determined by clinical microdialysis in morbidly obese patients undergoing abdominal surgery. Int J Antimicrob Agents. 2009;34(3):231235.
-
35.
Hites M., Taccone F.S., Wolff F., et al. Broad-spectrum β-lactams in obese non-critically ill patients. Nutr Diabetes. 2014;4:e119.
-
36.
Rich B.S., Keel R., Ho V.P., et al. Cefepime dosing in the morbidly obese patient population. Obes Surg. 2012;22:465-471.
-
37.
Newman D., Scheetz M.H., Adeyemi O.A., et al. Serum piperacillin/ tazobactam pharmacokinetics in a morbidly obese individual. Ann Pharmacother. 2007;41:1734-1739.
-
38.
Deman H., Verhaegen J., Willems L., et al. Dosing of piperacillin/ tazobactam in a morbidly obese patient [letter]. J Antimicrob Chemother. 2012;67:782-783.
-
39.
Sturm A.W., Allen N., Rafferty K.D., et al. Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients. Pharmacotherapy. 2014;34(1):28-35.
-
40.
Cheatham S.C., Fleming M.R., Healy D.P., et al. Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients. Int J Antimicrob Agents. 2013;41(1):52-56.
-
41.
Chen M., Nafziger A.N., Drusano G.L., et al. Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults. Antimicrob Agents Chemother. 2006;50:1222-1227.
-
42.
Zakrison T.L., Hille D.A., Namias N. Effect of body mass index on treatment of complicated intra-abdominal infections in hospitalized adults: comparison of ertapenem with piperacillin-tazobactam. Surg Infect (Larchmt). 2012;13:38-42.
-
43.
Itani K.M., Jensen E.H., Finn T.S., et al. Effect of body mass index and ertapenem versus cefotetan prophylaxis on surgical site infection in elective colorectal surgery. Surg Infect (Larchmt). 2008;9:131-137.
-
44.
Cheatham S.C., Fleming M.R., Healy D.P., et al. Steady-state pharmacokinetics and pharmacodynamics of meropenem in morbidly obese patients hospitalized in an intensive care unit. J Clin Pharmacol. 2014;54(3):324-330.
-
45.
Hites M., Taccone F.S., Wolff F., et al. Case-control study of drug monitoring of β-lactams in obese critically ill patients. Antimicrob Agents Chemother. 2013;57:708-715.
-
46.
Pai M.P., Cojutti P., Pea F. Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial infections. Clin Pharmacokinet. 2015;54(9):933-941.
-
47.
Kays M.B., Fleming M.R., Cheatham S.C., et al. Comparative pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients. Ann Pharmacother. 2014;48(2):178-186.
-
48.
Roberts J.A., Lipman J. Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility. Crit Care Med. 2013;41(2):489495.
-
49.
Chung E.K., Fleming M.R., Cheatham S.C., et al. Population Pharmacokinetics and Pharmacodynamics of Doripenem in Obese, Hospitalized Patients. Ann Pharmacother. 2017;51(3):209-218.
-
50.
Alobaid A.S., Hites M., Lipman J., et al. Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: A structured review. Int J Antimicrob Agents. 2016;47(4):259-268.
-
51.
Rybak M., Lomaestro B., Rotschafer J.C., et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66:82-98.
-
52.
Thom H., Thompson J.C., Scott D.A., et al. Comparative efficacy of antibiotics for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a systematic review and network meta-analysis. Curr Med Res Opin. 2015;31(8):1539-1551.
-
53.
Morrill H.J., Caffrey A.R., Noh E., et al. Vancomycin Dosing Considerations in a Real-World Cohort of Obese and Extremely Obese Patients. Pharmacotherapy. 2015;35(9):869-875.
-
54.
Hall R.G., Payne K.D., Bain A.M., et al. Multicenter evaluation of vancomycin dosing: emphasis on obesity. Am J Med. 2008;121:515-518.
-
55.
Bauer L.A., Black D.J., Lill J.S. Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol. 1998;54:621-625.
-
56.
Blouin R.A., Bauer L.A., Miller D.D., et al. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother. 1982;21:575-580.
-
57.
Grace E. Altered vancomycin pharmacokinetics in obese and morbidly obese patients: what we have learned over the past 30 years. J Antimicrob Chemother. 2012;67(6):1305-1310.
-
58.
Kullar R., Davis S.L., Levine D.P., et al. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis. 2011;52(8):975-981.
-
59.
Reynolds D.C., Waite L.H., Alexander D.P., et al. Performance of a vancomycin dosage regimen developed for obese patients. Am J Health Syst Pharm. 2012;69:944-950.
-
60.
Lodise T.P., Lomaestro B., Graves J., et al. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother. 2008;52(4):1330-1336.
-
61.
Pai M.P. Anti-infective Dosing for Obese Adult Patients: A Focus on Newer Drugs to Treat Methicillin-resistant Staphylococcus aureus Acute Bacterial Skin and Skin Structure Infections. Clin Ther. 2016;38(9):20322044.
-
62.
Lodise T.P., Patel N., Lomaestro B.M., et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis. 2009;49(4):507-514.
-
63.
Smith W.J., Drew R.H. Telavancin: a new lipoglycopeptide for gram-positive infections. Drugs Today (Barc). 2009;45(3):159-173.
-
64.
Drug @ FDA Database. US Food and Drug Administration. Vibativ Label 2009. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022110s000lbl.pdf. Accessed July, 28, 2017.
-
65.
Jauregui L.E., Babazadeh S., Seltzer E., et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis. 2005;41(10):1407-1415.
-
66.
Dunne M.W., Puttagunta S., Giordano P., et al. A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection. Clin Infect Dis. 2016;62(5):545-551.
-
67.
Dowell J.A., Goldstein B.P., Buckwalter M., et al. Pharmacokineticpharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic. J Clin Pharmacol. 2008;48(9):1063-1068.
-
68.
Schwartz S.N., Pazin G.J., Lyon J.A., et al. A controlled investigation of the pharmacokinetics of gentamicin and tobramycin in obese subjects. J Infect Dis. 1978;138(4):499-505.
-
69.
Blouin R.A., Mann H.J., Griffen W.O.Jr., et al. Tobramycin pharmacokinetics in morbidly obese patients. Clin Pharmacol Ther. 1979;26(4):508-512.
-
70.
Blouin R.A., Brouwer K.L., Record K.E., et al. Amikacin pharmacokinetics in morbidly obese patients undergoing gastric-bypass surgery. Clin Pharm. 1985;4(1):70-72.
-
71.
Bauer L.A., Edwards W.A., Dellinger E.P., et al. Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol. 1983;24(5):643-647.
-
72.
Leader W.G., Tsubaki T., Chandler M.H. Creatinine-clearance estimates for predicting gentamicin pharmacokinetic values in obese patients. Am J Hosp Pharm. 1994;51(17):2125-2130.
-
73.
Pai M.P., Nafziger A.N., Bertino J.S.Jr. Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients. Antimicrob Agents Chemother. 2011;55:4006-4011.
-
74.
Pai M.P. Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults. Pharmacotherapy. 2012;32:856-868.
-
75.
Abdullahi M., Annibale B., Capoccia D., et al. The eradication of Helicobacter pylori is affected by body mass index (BMI). Obes Surg. 2008;18:1450-1454.
-
76.
Cerqueira R.M., Manso M.C., Correia M.R., et al. Helicobacter pylori eradication therapy in obese patients undergoing gastric bypass surgery – fourteen days superior to seven days? Obes Surg. 2011;21: 1377-1381.
-
77.
Allard S., Kinzig M., Boivin G., et al. Intravenous ciprofloxacin disposition in obesity. Clin Pharmacol Ther. 1993;54:368-373.
-
78.
Hollenstein U.M., Brunner M., Schmid R., et al. Soft tissue concentrations of ciprofloxacin in obese and lean subjects following weight-adjusted dosing. Int J Obes Relat Metab Disord. 2001;25:354-358.
-
79.
Caldwell J.B., Nilsen A.K. Intravenous ciprofloxacin dosing in a morbidly obese patient. Ann Pharmacother. 1994;28:806.
-
80.
Kees M.G., Weber S., Kees F., et al. Pharmacokinetics of moxifloxacin in plasma and tissue of morbidly obese patients. J Antimicrob Chemother. 2011;66:2330-2335.
-
81.
Luque S., Grau S., Valle M., et al. Levofloxacin weight-adjusted dosing and pharmacokinetic disposition in a morbidly obese patient [letter]. J Antimicrob Chemother. 2011;66:1653-1654.
-
82.
Cook A.M., Martin C., Adams V.R., et al. Pharmacokinetics of intravenous levofloxacin administered at 750 milligrams in obese adults. Antimicrob Agents Chemother. 2011;55:3240-3243.
-
83.
Muzevich K.M., Lee K.B. Subtherapeutic linezolid concentrations in a patient with morbid obesity and methicillin-resistant Staphylococcus aureus pneumonia: case report and review of the literature. Ann Pharmacother. 2013;47(6):e25.
-
84.
Tsuji Y., Hiraki Y., Matsumoto K., et al. Evaluation of the pharmacokinetics of linezolid in an obese Japanese patient. Scand J Infect Dis. 2012;44(8):626629.
-
85.
Stein G.E., Schooley S.L., Peloquin C.A., et al. Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis. Ann Pharmacother. 2005;39:427-432.
-
86.
Bhalodi A.A., Papasavas P.K., Tishler D.S., et al. Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults. Antimicrob Agents Chemother. 2013;57:1144-1149.
-
87.
Zhanel G.G., Love R., Adam H., et al. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens. Drugs. 2015;75(3):253-270.
-
88.
Flanagan S., Passarell J., Lu Q., et al. Tedizolid population pharmacokinetics, exposure response, and target attainment. Antimicrob Agents Chemother. 2014;58(11):6462-6470.
-
89.
Pai M.P. Pharmacokinetics of Tedizolid in Morbidly Obese and Covariate-Matched Nonobese Adults. Antimicrob Agents Chemother. 2016;60(8):4585-4589.
-
90.
Van Wart S.A., Owen J. S., Ludwig E.A., et al. Population Pharmacokinetics of Tigecycline in Patients with Complicated Intra-Abdominal or Skin and Skin Structure Infections. Antimicrob Agents Chemother. 2006;50(11):37013707.
-
91.
Passarell J., Ludwig E., Liolios K., et al. Exposure-response analyses of tigecycline tolerability in healthy subjects. Diagn Microbiol Infect Dis. 2009;65(2):123-129.
-
92.
Pai M.P. Serum and urine pharmacokinetics of tigecycline in obese class III and normal weight adults. J Antimicrob Chemother. 2014;69(1):190-199.
-
93.
Dvorchik B., Arbeit R.D., Chung J., et al. Population Pharmacokinetics of Daptomycin. Antimicrob Agents Chemother. 2004;48(8):2799-2807.
-
94.
Dvorchik B.H., Damphousse D. The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects. J Clin Pharmacol. 2005;45(1):48-56.
-
95.
Bhavnani S.M., Rubino C.M., Ambrose P.G., et al. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis. 2010;50(12):1568-1574.
-
96.
Bookstaver P.B., Bland C.M., Qureshi Z.P., et al; SERGE-45 Investigators. Safety and effectiveness of daptomycin across a hospitalized obese population: results of a multicenter investigation in the southeastern United States. Pharmacotherapy. 2013;33(12):1322-1330.
-
97.
Ng J.K., Schulz L.T., Rose W.E., et al. Daptomycin dosing based on ideal body weight versus actual body weight: comparison of clinical outcomes. Antimicrob Agents Chemother. 2014;58(1):88-93.
-
98.
Davido B., Bouchand F., Calin R., et al. High rates of off-label use in antibiotic prescriptions in a context of dramatic resistance increase: a prospective study in a tertiary hospital. Int J Antimicrob Agents. 2016;47:490-494.
-
99.
Somova M.N., Batishheva G.A. Legal aspects of prescribing off-label. Prikladnye informacionnye aspekty mediciny. 2016;19(3):139-143. Russian.
-
100.
Food and Drug Administration Modernization Act of 1997, 21 U.S.C. §360aa, §551 (1997).
-
101.
Pereverzev A.P., Lepahin V.K. Modern view on the problem of the use of medicines in violation of the instructions. Medicinskij sovet. 2013;4:110111. Russian.